Thursday 16 October, 2025
Objectives: Cardiopulmonary bypass (CPB) is an extracorporeal medical procedure that replaces heart and lung function. CPB can alter pharmacokinetic (PK)…
Read moreOral: Lewis Sheiner Student Session
Integrating Reinforcement Learning and PK-PD modelling to enable precision dosing: a multi-objective optimization for the treatment of Polycithemia Vera patients with Givinostat
Thursday 16 October, 2025
Objectives: Precision Dosing is an emerging approach aiming to optimize and customize the dose and the treatment schedule at individual…
Read moreOptimizing dosing strategies for post-kala-azar dermal leishmaniasis: a geographical comparison of systemic and skin pharmacokinetics and pharmacodynamics of antileishmanial drugs
Thursday 16 October, 2025
Objectives: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatological complication that arises after the successful treatment of the neglected tropical disease…
Read moreJoint modeling of biomarkers dynamics and survival with competing risks to predict the prognostic of patients hospitalized with severe infectious diseases
Thursday 16 October, 2025
Objectives: Nowadays, most hospitals are equipped with laboratory information systems that routinely gather all results of biological analyses prescribed by the…
Read moreMechanistic modeling of the long-term dynamics of viral markers to predict the outcome of combination therapy in chronic HBV and HDV infections
Thursday 16 October, 2025
Background. Nearly 300 million people worldwide are chronically infected with Hepatitis B virus (HBV). One important specificity of HBV is…
Read moreA generative and causal pharmacokinetic model for haemophilia A: towards an unified model for all factor VIII concentrates.
Thursday 16 October, 2025
Objectives: Several population pharmacokinetic (PK) models have been developed for the wide range of recombinant factor VIII (rFVIII) concentrates used…
Read moreIn silico assessment of adaptive trial design for TB regimen development
Thursday 16 October, 2025
Objectives: Current tuberculosis (TB) regimen development is in dire need of rapid innovation; the current 6-month standard of care has…
Read moreBayesian modelling of individual lesions dynamics and survival to characterize response to immunotherapy cancer treatments
Thursday 16 October, 2025
Context: In oncology clinical trials, a common marker of tumor size is the Sum of Longest Diameters (SLD) of target…
Read moreLogistic regression-based approach to assess heterogeneity in vaccine efficacy using immunogenicity measurements in phase 3 clinical trials
Thursday 16 October, 2025
Objectives: This work introduces a novel use of immune response biomarkers to help identify baseline covariates affecting vaccine efficacy (VE). …
Read moreA translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables
Thursday 16 October, 2025
Objectives: Cardiovascular safety issues are among the major causes of safety-related attrition in drug development.1 Early prediction and quantification of…
Read more